What we do

CLISYNE aims to:

To promote the use of systems biology, computerized analyses, and artificial intelligence, in all the steps of drug discovery for diseases of the CNS (see workflow).

  • Mechanistic studies in cellular and animal models
  • Target identification
  • Drug screens
  • Preclinical drug validation
  • Drug delivery
  • Biomarker identification
  • Patient stratification in clinical trials

Specific actions:

  • Career development
  • Education
  • Funding
  • Networking
  • Research and translation

CLISYNE is timely because: 

  • The data, theoretical developments and methodology are ripe to have an impact on therapeutics. 
  • The traditional duet of drug discovery ‘one-compound-one-molecular target’ does not work. Numerous promising candidates have failed in clinical trials due to lack of efficacy or serious side effects.
  • The overarching goal of CLISYNE is to develop efficacious multi-target drugs with no side effects.

We want to convince:

  • Neurobiologists and neurologists of the power of advanced systems biology in data mining and drug discovery.
  • Experts in drug discovery of the importance of viewing CNS diseases from the point of view of systems neuroscience as the result of dysfunctional neural networks.

Workflow of drug discovery for CNS diseases

Key ideas:

  • Therapies are cell specific.
  • Circuit dysfunction is at the core of CNS diseases.
  • Systems-based tools should be used throughout the process of drug discovery from the identification of pathological mechanisms to patient stratification in clinical trials.

CLISYNE aims to:

To promote the use of systems biology, computerized analyses, and artificial intelligence, in all the steps of drug discovery for diseases of the CNS.

  • Mechanistic studies in cellular and animal models
  • Target identification
  • Drug screens
  • Preclinical drug validation
  • Drug delivery
  • Biomarker identification
  • Patient stratification in clinical trials

Specific actions

  • Career development
  • Education
  • Funding
  • Networking
  • Research and translation

CLISYNE is timely because: 

  • Powerful systems tools already exist to mine big data and build models. The data, theoretical developments and methodology are ripe to have an impact on therapeutics. 
  • The traditional duet of drug discovery ‘one-compound-one-molecular target’ does not work. Numerous promising candidates have failed in clinical trials due to lack of efficacy or serious side effects.
  • The overarching goal of CLISYNE is to develop efficacious multi-target drugs with no side effects.

We want to convince:

  • Neurobiologists and neurologists of the power of advanced systems biology in data mining and drug discovery.
  • Experts in drug discovery of the importance of viewing CNS diseases from the point of view of systems neuroscience as the result of dysfunctional neural networks.

Key ideas in drug discovery for CNS diseases

  • Therapies are cell specific.
  • Circuit dysfunction is at the core of CNS diseases.
  • Systems-based tools should be used throughout the process of drug discovery from the identification of pathological mechanisms to patient stratification in clinical trials.